AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01575262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-cash incentives
Description: Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
Study NCT01575262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring physical activity levels
Description: For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
Study NCT03776617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scalp block
Description: Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
Study NCT03776617 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: scalp block
Description: Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
Study NCT06390865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06390865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06390865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06390865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06390865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT00595335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Study NCT00595335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
Study NCT03008746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sputum
Study NCT03336606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI0562
Description: Surgical resection of tumor
Study NCT03008746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral wash
Study NCT02148458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
Study NCT02328300 — intervention group
Intervention type: DRUG
Intervention: FLT PET/MR
Description: Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
Study NCT00268788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous immunoglobulin
Description: Individually dosed, given twice a week.
Study NCT00268788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: Individual dose and frequency
Study NCT03570697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Participants will receive evolocumab (AMG 145) subcutaneous monthly.
Study NCT03570697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo subcutaneous monthly.
Study NCT03570697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin therapy
Description: high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.
Study NCT03570697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin therapy
Description: high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.
Study NCT03141437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT03141437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study NCT03141437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT00595335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
Study NCT03307980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06838435 (formerly SPK-9001)
Description: Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
Study NCT00807209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose SKY0402
Description: Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
Study NCT00807209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose SKY0402
Description: Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
Study NCT00807209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
Study NCT05358730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
Study NCT05358730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise
Description: Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
Study NCT03141437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT03141437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use decision-making website
Study NCT05358730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization (IASTM)
Description: IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.
Study NCT05358730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks.
Study NCT05358730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks.
Study NCT02148458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
Study NCT00659919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00807209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl via PCA
Description: Fentanyl via PCA
Study NCT00807209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl via PCA
Description: Fentanyl via PCA
Study NCT00807209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine via epidural
Description: Bupivacaine via epidural
Study NCT00807209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine via epidural
Description: Bupivacaine via epidural
Study NCT03574337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: No additional information
Study NCT03574337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine/glycopyrolate
Description: No additional information
Study NCT02447887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
Study NCT02447887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated IFN-alpha 2b
Description: Weekly injection
Study NCT04118946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet enriched plasma
Description: PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
Study NCT03141437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03141437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiral PDS Plus
Description: The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiral MONOCRYL Plus
Description: The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDS Plus
Description: PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS Plus
Description: PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MONOCRYL Plus
Description: MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MONOCRYL Plus
Description: MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study NCT02662192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + health education+ auditory rehabilitation
Description: comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
Study NCT02662192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: auditory rehabilitation alone
Description: 10 weeks of one hour per week of group auditory rehabilitation
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VICRYL Plus
Description: VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study NCT03792737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VICRYL Plus
Description: VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
Study NCT00085839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva (Trademark) (erlotinib HCl, OSI-774)
Description: Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
Study NCT00085839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination carboplatin and paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
Study NCT04598425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTi)
Description: Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
Study NCT01427478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFATINIB
Description: AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
Study NCT01427478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AFATINIB
Description: placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
Study NCT00683787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV once every 3 weeks
Study NCT00683787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV once every 3 weeks
Study NCT00683787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral vandetanib once daily
Study NCT03651908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Flap Surgery
Description: After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.
Study NCT03651908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Flap Surgery
Description: After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.
Study NCT01411488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecal management system
Description: rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
Study NCT01411488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal management system
Description: rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
Study NCT01110044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 251154 vaccine
Description: Intramuscular, single dose
Study NCT01110044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular, four doses
Study NCT01110044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, four doses
Study NCT00659919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Study NCT04045249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home based food
Description: Home based food is compare able to RUTF
Study NCT00757562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine syrup: 1.25 mg (2.5 mL) for subjects >=2 to \<6 years, 2.5 mg (5 mL) for subjects >=6 to \<12 years, orally once daily in the morning for 36 days.
Study NCT00757562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo syrup: 2.5 mL for subjects >=2 to \<6 years, 5 mL for subjects >=6 to \<12 years, orally once daily in the morning for 36 days.
Study NCT02027298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: by SC injection of 125 mg weekly for 6 months
Study NCT05029596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Group
Description: A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
Study NCT05029596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Group
Description: All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
Study NCT01110044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: Intramuscular, four doses
Study NCT02280161 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies
Study NCT01535430 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain mapping
Description: Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
Study NCT04134325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
Study NCT04134325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
Study NCT02577406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-221
Description: Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
Study NCT02577406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSC
Description: Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
Study NCT02577406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
Study NCT02577406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
Study NCT02577406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Description: continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
Study NCT02577406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate-dose cytarabine (IDAC)
Description: 28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
Study NCT02998437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10mg
Description: Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
Study NCT02998437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day